
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 4, 2026, 7:05 AM ET
Unicycive Therapeutics CEO Shalabh Gupta, M.D., will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026.
$UNCYKidney diseaseOLC reviewManufacturing and dilution risk
UNCY Stock Hub: Unicycive Therapeutics News, OLC and FDA Review
A second drug-product vendor changes the OLC remediation package, while manufacturing review, a March FDA target date and potential launch costs remain separate tests. June resources and contingent warrant proceeds need different treatment. October 30 close: $3.74.
Full research report · PDF
Unicycive Therapeutics ($UNCY), research as of October 21, 2026
15 pages covering the OLC resubmission and vendor problem, clinical denominators, financial resources, litigation and warrant dilution. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Announced regulatory target date
March 25, 2027 · OLC PDUFA target
The FDA classified the accepted resubmission as a Class II response with a six-month review. The application includes data from a second drug-product vendor.
A target action date is distinct from approval; any inspection decision and the outcome of manufacturing review remain with the FDA. Earlier, Chief Executive Officer Shalabh Gupta, M.D., presents at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026 at 2:30 p.m. ET, with a webcast on the company website. Conference announcement
UNCY stock at a glance
Close · October 30, 2026
$3.74
Regular session; -1.84% versus $3.8100 on October 29.
Cash + securities · June 30
$61.425M
Cash $44.185M plus bonds $17.240M; not current cash. Primary source
Historical monthly cash use
$2.3075M
H1 operating use divided by six; calculated, not a forecast. Primary source
Company runway guidance
Into H2 2027
September 29 guidance, subject to the operating plan. Primary source
PDUFA target action date
March 25, 2027
Announced October 21; target, not an approval promise. Primary source
Common shares · August 12
27,855,257
Reported count; excludes later changes and potential instruments. Primary source
Director options awarded
27,000
October 28 award at $3.76; filing October 29, not a purchase. Primary source
Where Unicycive Therapeutics stands now
The FDA accepted the OLC resubmission on October 21 as a Class II response and set a March 25, 2027 PDUFA target. Acceptance is not proof of manufacturing compliance, approval or commercial adoption. June cash and securities of $61.425 million predate subsequent spending. A director’s Form 4 filed October 29 reports compensation awards on October 28: 3,350 restricted stock units and 27,000 options at $3.76, rather than an open-market share purchase.
A vendor change is not proof of a successful FDA review. Two review cycles ended in complete response letters, and the new package remains under review. Potential warrant proceeds depend on exercise, while legal disputes and further financing can affect per-share claims.
The constructive case
A favorable manufacturing review and eventual FDA decision could support an OLC launch after the second-vendor package. Company runway guidance into the second half of 2027 provides time under the plan, while any warrant exercise could contribute funding only if holders act.
The cautious case
A further manufacturing problem, a longer review or higher launch spending can consume resources before product revenue. Two disclosed securities actions add uncertainty, and warrants, awards and later financing can materially enlarge the share denominator.
Latest Unicycive Therapeutics news
Nov 4, 2026
Unicycive Therapeutics to present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Unicycive Therapeutics, Inc. announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026. A link to the live and archived webcast is available on the Unicycive website under the Investors section, Events and Presentations. The company is developing oxylanthanum carbonate, a phosphate binding agent for hyperphosphatemia in dialysis patients with chronic kidney disease.
Oct 29, 2026
Director compensation awards reported on Form 4
The filing reports October 28 awards of 3,350 restricted stock units and 27,000 stock options with a $3.76 exercise price. Transaction code A denotes awards; this is not an open-market purchase.
Oct 21, 2026
FDA accepts OLC resubmission and assigns March target
The accepted application follows a Class II six-month review with a March 25, 2027 PDUFA target. The company does not know whether the FDA will inspect the new vendor before approval; acceptance is not approval.
Sep 29, 2026
OLC resubmitted with a second drug-product vendor
The package includes twelve months of stability data and in-vitro bridging between the suppliers. The company keeps both vendors for redundancy and guides financial resources into H2 2027.
Sep 28, 2026
A second securities class action is disclosed
The filing reports a second securities action, filed September 3. Allegations remain disputed, and the dated disclosure does not establish a current judicial outcome.
Aug 12, 2026
June balance sheet and operating cash use reported
Cash and securities were $61.425 million, with no borrowings and H1 operating cash use of $13.845 million. The reported share count was 27,855,257; balances remain historical.
UNCY stock catalysts: OLC manufacturing review and funding
- November 10, 2026 · 2:30 p.m. ET — Presentation by Chief Executive Officer Shalabh Gupta, M.D., at the Guggenheim 3rd Annual Healthcare Innovation Conference; live and archived webcast in the Investors section of the company website. Scheduled investor event
- March 25, 2027 — PDUFA target action date for the accepted OLC resubmission. FDA target announced by company
- During review — Manufacturing assessment and any inspections; no confirmed inspection date. Regulatory process
- Into H2 2027 — Company financial runway guidance; spending and financing can change it. Conditional company outlook
OLC review announcement · Resubmission and runway · Guggenheim conference
OLC: clinical denominators and the manufacturing review
UNI-494 is licensed from Sphaera Pharma Pte. Ltd. and is a prodrug cleaved by esterases to nicorandil; the annual filing describes selective activation of the mitochondrial KATP channel’s SUR2B subunit. OLC’s Renazorb program and related rights were acquired from Spectrum Pharmaceuticals in September 2018. These clarify asset identity and provenance without establishing clinical efficacy. Unicycive Form 10-Q (SEC). Unicycive Form 10-K (SEC).
OLC is a lanthanum-based phosphate binder intended for hyperphosphatemia in adults with chronic kidney disease on dialysis. In the published Phase 2 trial, 86 patients received treatment and 78 entered maintenance; 71 of those 78 achieved phosphate control during titration. Thus the reported 91% is not 91% of all 86 treated patients. Among the 71 achieving control, 49 (69%) did so with three tablets a day or fewer. Three of 86 patients (4%) discontinued because of treatment-related adverse events. These denominators distinguish the tolerability population from the efficacy-evaluable subset.
UNCY cash, runway and potential share dilution
The cash trail on the disclosed dates: $41.269M at December 31, 2025; $57.1M as of the May 11, 2026 first-quarter release; $61.425M at June 30, 2026. The balance went up over the half because the at-the-market programme raised $34.0 million net, not because the business consumed less.
Burn. Operating cash use was $13.845 million over the first half of 2026 — $2.31 million a month, against $17.323 million in the first half of 2025. For the full year 2025 it was $31.317 million, about $2.61 million a month. So the rate has come down.
Merlintrader Health Score · $UNCY
2.80out of 5
Assessed October 4, 2026; regulatory catalyst updated October 21, 2026. Weighted calculation: 3.5×30% + 3.0×30% + 2.0×20% + 2.5×10% + 2.0×10% = 2.80. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.
Red flags
- The FDA review target does not guarantee approval or launch.
- June liquidity is historical; a runway calculation is not an October cash forecast.
- Warrant proceeds require exercise and are not automatic approval funding.
- Two securities actions and potential share issuance create distinct risks.
UNCY Stock FAQ: Unicycive Therapeutics Questions Answered
What is Unicycive’s OLC PDUFA date?
Unicycive announced an OLC PDUFA target action date of March 25, 2027 on October 21, 2026. FDA accepted the resubmitted application as a Class II response with a six-month review, including the package for a second drug-product vendor. FDA review schedule.
Is Unicycive’s oxylanthanum carbonate FDA approved?
No: as of November 2, 2026, Unicycive’s oxylanthanum carbonate remained investigational following two complete response letters. The accepted resubmission is under FDA review for hyperphosphatemia in chronic kidney disease patients on dialysis, with a March 25, 2027 target action date. Current application status. June complete response letter.
How much cash does Unicycive have, and how long will it last?
Unicycive reported $61.425 million cash and investments at June 30, 2026, and on September 29 guided funding into the second half of 2027. The balance comprised $44.185 million cash and $17.240 million corporate bonds, with no debt. First-half operating cash use was $13.845 million, averaging a calculated $2.3075 million monthly. The filing stated no substantial doubt about continued operations. Liquidity and operating cash use. Updated funding outlook.
Is UNCY stock at risk of dilution?
Yes: Unicycive reported 19,624,727 potentially dilutive common-equivalent shares at June 30, 2026 against 27,855,257 common shares outstanding. Adding the inventory gives approximately 47.48 million, or 70.5% more, before exercise, vesting and conversion conditions. Preferred warrants were already exercisable; their expiration dates depend on FDA approval, TDAPA approval and later sales reporting. Those events do not automatically issue every share or generate all potential proceeds. Shares and warrant conditions.
When does Unicycive report earnings?
As of November 2, 2026, Unicycive had not announced its next quarterly earnings date. The latest quarterly results were released August 12 for the period ended June 30; its official news archive and event calendar provide future announcements. Company announcements. Investor calendar. Latest quarterly results.
What does Unicycive Therapeutics do?
Unicycive develops medicines for patients with kidney disease. Its lead candidate oxylanthanum carbonate is an investigational oral phosphate binder intended to treat hyperphosphatemia in chronic kidney disease patients on dialysis, with its resubmitted U.S. application under FDA review. Business and lead product.
Why did FDA issue complete response letters for Unicycive’s OLC?
Unicycive said the two OLC complete response letters, including the June 29, 2026 letter, concerned manufacturing deficiencies at a third-party vendor and requested no new efficacy or safety trial data. The FDA letter also requires an integrated safety update and reserves labeling comments. Manufacturing compliance remains part of the application’s regulatory assessment. Company account of review history. FDA complete response letter.
What changed in Unicycive’s OLC resubmission?
Unicycive’s September 29, 2026 resubmission adds a second drug-product vendor with twelve months of stability data and in-vitro bridging results. The company reported that facility’s March 2024 no-action-indicated inspection and planned to retain both suppliers. The original vendor’s assigned inspection had not occurred as of that announcement; the new package is being assessed in the current review. Manufacturing package and vendor history. Resubmission acceptance.
Primary sources
- November 4, 2026 — Presentation at the Guggenheim 3rd Annual Healthcare Innovation Conference, November 10
- October 29, 2026 — Director compensation awards reported on Form 4
- October 21, 2026 — FDA accepts OLC resubmission and assigns March target
- September 29, 2026 — OLC resubmitted with a second drug-product vendor
- September 28, 2026 — A second securities class action is disclosed
- August 12, 2026 — June balance sheet and operating cash use reported
- June 29, 2026 — FDA issues the second complete response letter
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent analysis and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $UNCY or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, official trial registries and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single decision can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
Educational and editorial content only. This report is not personalised financial advice, a solicitation, or a recommendation to buy, sell or hold any security. Biotech and small and mid-cap stocks can be extremely volatile and may result in partial or total loss of capital. Regulatory outcomes, manufacturing inspections, litigation, financing availability, dilution and commercial execution all remain uncertain.



